Catalyst Biosciences

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the merger of Catalyst Biosciences, Inc. (NasdaqCM: CBIO) and GNI Group Ltd. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company's shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost.

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

NEW ORLEANS, March 9, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating Catalyst Biosciences, Inc. (NasdaqCM: CBIO) in connection with its acquisition of the F351 program, a next-generation fibrosis drug, from GNI Group Ltd. and, in a separate transaction, its acquisition of a controlling interest in Beijing Continent for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (Series X) with economic rights equivalent to Catalyst's common stock. Each share of Series X preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company's shareholders.

CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO

DCP Midstream

Malvern Bancorp

Shore Bancshares

NEW YORK , March 7, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law305 Broadway, 7th Floor New York, NY 10007MLVF (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com DCP Midstream, LP (NYSE: DCP) Weiss Law is investigating possible violations of law connected with the proposed acquisition of DCP Midstream, LP (NYSE: DCP) by Phillips 66.

SHAREHOLDER ALERT: Weiss Law Reminds DCP, MLVF, SHBI, and CBIO Shareholders About Its Ongoing Investigations

Catalyst Biosciences (NASDAQ: CBIO ) stock is rocketing higher on Tuesday after the company announced an asset purchase agreement with GC Biopharma. That agreement has Catalyst Biosciences selling three of its programs related to orphan hematology disorders to the company.

Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates.

Catalyst Biosciences Provides Corporate Update

Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development.

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

NEW YORK , Jan. 4, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Catalyst Biosciences, Inc. (NASDAQ: CBIO), relating to the proposed purchase of F351, a chemical entity owned by GNI Group Ltd. Click here for more information: https://www.monteverdelaw.com/case/catalyst-biosciences-inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIO

NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. ("Catalyst" or the "Company") (NASDAQ: CBIO), in connection with the proposed purchase of GNI Group Ltd.'s ("GNI") proprietary new chemical entity F351 ("F351").

SHAREHOLDER ALERT: Weiss Law Investigates Catalyst Biosciences, Inc.

Wilmington, Delaware--(Newsfile Corp. - December 29, 2022) - Rigrodsky Law, P.A. is investigating Catalyst Biosciences, Inc. ("Catalyst") (NASDAQ CM: CBIO) regarding possible breaches of fiduciary duties and other violations of law related to Catalyst's agreement to merge with GNI Group Ltd.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-catalyst-biosciences-inc. To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. Merger

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Catalyst Biosciences, Inc. (NASDAQ: CBIO) and GNI Group Ltd. is fair to Catalyst shareholders.

CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders

Acquires F351, a Phase 3 Drug to Treat Fibrosis

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

Company to Announce a Record Date for Initial Distribution in Due Course Company to Announce a Record Date for Initial Distribution in Due Course

Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022.

Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, shareholders should expect an initial cash distribution of $45 million.

Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock

FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences,

JDS1, LLC Terminates Proxy Contest at Catalyst's 2022 Annual Meeting

Encourages Stockholders to Vote on the WHITE Proxy Card Encourages Stockholders to Vote on the WHITE Proxy Card

Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board

ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan  Catalyst Urges Stockholders to VOTE “FOR” All of the Company's Nominees

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company's Nominees on the WHITE Proxy Card

Provides Details on Current Board's Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution

Catalyst Biosciences Publishes New Investor Presentation

JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst's Nominees at the Company's 2022 Annual Meeting

Catalyst Biosciences Announces Support from Largest Single Stockholder

FORT LEE, N.J.--(BUSINESS WIRE)--JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to its fellow stockholders. JDS1 is urging shareholders to vote on the GOLD proxy card to elect its slate of th

JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders

Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations

Catalyst Biosciences Sends Letter to Stockholders

Court Denies JDS1's Motion for Expedited Proceedings

News for Catalyst Biosciences Stock (CBIO)